{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T17:51:38Z","timestamp":1760205098205,"version":"3.44.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jim.2020.112939","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T12:58:51Z","timestamp":1607518731000},"page":"112939","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Development of competitive inhibition ELISA as an effective potency test to analyze human rabies vaccines and assessment of the antigenic epitope of rabies glycoprotein"],"prefix":"10.1016","volume":"492","author":[{"given":"Dipen","family":"Soni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itishree","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asha D.","family":"Mallya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praveen","family":"Kamthe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Sahai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil Kumar","family":"Goel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasad S.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev M.","family":"Dhere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jim.2020.112939_bb0005","series-title":"Program and abstracts of the RITA XIX","article-title":"Fully human monoclonal antibody 17C7 neutralizes rabies virus endemic to Asia","author":"Babcock","year":"2008"},{"issue":"4","key":"10.1016\/j.jim.2020.112939_bb0010","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0264-410X(88)90185-5","article-title":"NIH-test, a problematic method for testing potency of inactivated rabies vaccine \/ R. Barth, G. Diderrich, E. Weinmann","volume":"6","author":"Barth","year":"1988","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2020.112939_bb0015","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1128\/jvi.65.8.4198-4203.1991","article-title":"Antigenicity of rabies virus glycoprotein","volume":"65","author":"Benmansour","year":"1991","journal-title":"J. Virol."},{"key":"10.1016\/j.jim.2020.112939_bb0020","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.biologicals.2017.02.002","article-title":"G-protein based ELISA as a potency test for rabies vaccines","volume":"46","author":"Chabaud-Riou","year":"2017","journal-title":"Biologicals"},{"key":"10.1016\/j.jim.2020.112939_bb0025","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejpb.2018.08.006","article-title":"Aure Saulnier Biophysical virus particle specific characterization to sharpen the definition of virus stability","volume":"132","author":"Clenet","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"year":"2018","author":"Dianna","series-title":"International Collaborative Study to Assess the Suitability of the Candidate 7 th WHO International Standard for Rabies Vaccine","key":"10.1016\/j.jim.2020.112939_bb0030"},{"key":"10.1016\/j.jim.2020.112939_bb0035","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/0042-6822(83)90349-5","article-title":"Chemical and immunological analysis of the rabies soluble glycoprotein","volume":"124","author":"Dietzschold","year":"1983","journal-title":"Virology"},{"key":"10.1016\/j.jim.2020.112939_bb0040","series-title":"Rabies Vaccine for Human use Prepared in Cell Cul-Tures","first-page":"822","volume":"04","author":"European Pharmacopoeia","year":"2008"},{"key":"10.1016\/j.jim.2020.112939_bb0045","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1006\/biol.1996.0012","article-title":"Use of ELISA for in vitro potency test of rabies vaccines for animal use","volume":"24","author":"Gamoh","year":"1996","journal-title":"Biologicals"},{"key":"10.1016\/j.jim.2020.112939_bb0050","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1016\/j.vaccine.2013.10.019","article-title":"A relevant in vitro ELISA test in alternative to the in vivo NIH test for human rabies vaccine batch release","volume":"31","author":"Gibert","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2020.112939_bb0055","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1099\/0022-1317-83-12-3045","article-title":"Studies on the different conditions for rabies virus neutralization by monoclonal antibodies #1-46-12 and #7-1-9","volume":"83","author":"Irie","year":"2002","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.jim.2020.112939_bb0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.provac.2011.10.004","article-title":"Alternative methods and strategies to reduce, refine, and replace animal use for human vaccine post-licensing safety testing: state of the science and future directions","volume":"5","author":"Isbrucker","year":"2011","journal-title":"Proc. Vaccinol."},{"key":"10.1016\/j.jim.2020.112939_bb0065","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1099\/0022-1317-64-4-843","article-title":"Anti- genic sites on the CVS rabies virus glycoprotein analysis with monoclonal antibodies","volume":"64","author":"Lafon","year":"1983","journal-title":"J. Gen. Virol."},{"issue":"4","key":"10.1016\/j.jim.2020.112939_bb0070","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0092-1157(85)80042-1","article-title":"Use of a monoclonal antibody for quantitation of rabies vaccine glycoprotein by enzyme immunoassay","volume":"13","author":"Lafon","year":"1985","journal-title":"J. Biol. Stand."},{"key":"10.1016\/j.jim.2020.112939_bb0075","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1348-0421.1998.tb02270.x","article-title":"Antigenic and functional analyses of glycoprotein of rabies virus using monoclonal antibodies","volume":"42","author":"Luo","year":"1998","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.jim.2020.112939_bb0080","series-title":"Replacement, Reductio and refinement of aimal experiments in the development and control of biological producs Deeeeev.iol.and","first-page":"37","article-title":"WHO activities towards the three Rs n the development and control of biological products","author":"Milstien","year":"1996"},{"key":"10.1016\/j.jim.2020.112939_bb0085","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.vaccine.2016.12.039","article-title":"Replacement of in vivo human rabies vaccine potency testing by in vitro glycoprotein quntitation using ELISA-Results of an international collaborative study","volume":"35","author":"Morgeaux","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2020.112939_bb0090","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.biologicals.2005.07.004","article-title":"A simple immuno-capture ELISA to estimate rabies viral glycoprotein antigen in vaccine manufacture","volume":"34","author":"Nagarajan","year":"2006","journal-title":"Biologicals"},{"issue":"8","key":"10.1016\/j.jim.2020.112939_bb0095","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1128\/CVI.00204-10","article-title":"Recombinant diabody-based im- munocapture enzyme-linked immunosorbent assay for quantification of rabies virus glycoprotein","volume":"17","author":"Nimmagadda","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"issue":"4","key":"10.1016\/j.jim.2020.112939_bb0100","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/1045-1056(90)90037-Z","article-title":"In vitro rabies vaccine potency appraisal by ELISA: advantages of the immunocapture method with a neutralizing anti-glycoprotein monoclonal antibody","volume":"18","author":"Perrin","year":"1990","journal-title":"Biologicals"},{"year":"1996","series-title":"Rabies virus Charles E. Rupprecht. Medical Microbiology","key":"10.1016\/j.jim.2020.112939_bb0105"},{"issue":"1\u20132","key":"10.1016\/j.jim.2020.112939_bb0110","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0166-0934(95)01999-5","article-title":"Rabies vaccine potency control:comparison of ELISA systems for antigenicity testing","volume":"58","author":"Rooijakkers","year":"1996","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jim.2020.112939_bb0115","series-title":"Laboratory Techniques in Rabies","first-page":"279","article-title":"The NIH test for potency","author":"Seligmann","year":"1973"},{"key":"10.1016\/j.jim.2020.112939_bb0120","first-page":"2800","article-title":"Vaccine Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates","volume":"25","author":"Sloan","year":"2007"},{"key":"10.1016\/j.jim.2020.112939_bb0125","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.biologicals.2012.07.005","article-title":"Report on the international workshop on alternative methods for human and veterinary rabies vaccine testing: state of the science and planning the way forward","volume":"40","author":"Stokes","year":"2012","journal-title":"Biologicals"},{"issue":"4","key":"10.1016\/j.jim.2020.112939_bb0130","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0092-1157(89)80001-0","article-title":"Standardization of an enzyme immunoassay for the in vitro potency assay of inactivated tissue culture rabies vaccines: determination of the rabies virus glycoprotein with polyclonal antisera","volume":"17","author":"Thraenhart","year":"1989","journal-title":"J. Biol. Stand."},{"key":"10.1016\/j.jim.2020.112939_bb0135","series-title":"Some observations related to the validity of potency test for rabies vaccine\/ G.S. Turner\/\/Symp.Ser.Immunobiol.Stand","first-page":"324","volume":"Vol. 21","author":"Turner","year":"1974"},{"key":"10.1016\/j.jim.2020.112939_bb0140","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.antiviral.2011.06.002","article-title":"G glycoprotein amino acid residues required for human monoclonal antibody RAB1 neutralization are conserved in rabies virus street isolates","volume":"91","author":"Wang","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jim.2020.112939_bb0145","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.biologicals.2018.06.003","article-title":"Development of a relative potency test using ELISA for human rabies vaccines","volume":"55","author":"Wang","year":"2018","journal-title":"Biologicals"},{"key":"10.1016\/j.jim.2020.112939_bb0150","series-title":"Technical Report Series 941: Recommendations for Inactivated Rabies Vaccine for Human use Produced in Cell Substrates and Embryonated Eggs; Geneva","first-page":"83","author":"WHO","year":"2007"},{"key":"10.1016\/j.jim.2020.112939_bb0155","series-title":"WHO TRS 1016","article-title":"Expert Committee on Biological Standardization: sixty-ninth report","author":"WHO","year":"2019"},{"key":"10.1016\/j.jim.2020.112939_bb0160","series-title":"Laboratory techniques in rabiesMeslin F-X","article-title":"The NIH test for potency. Chapter 37","author":"Wilbur","year":"1996"}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175920302337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175920302337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T16:39:04Z","timestamp":1758299944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022175920302337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":32,"alternative-id":["S0022175920302337"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2020.112939","relation":{},"ISSN":["0022-1759"],"issn-type":[{"type":"print","value":"0022-1759"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of competitive inhibition ELISA as an effective potency test to analyze human rabies vaccines and assessment of the antigenic epitope of rabies glycoprotein","name":"articletitle","label":"Article Title"},{"value":"Journal of Immunological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jim.2020.112939","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112939"}}